Mark Zipkin, Author at Labiotech.eu

About

Mark Zipkin is a freelance writer and consultant for the biotech and pharma industry, and a Central Operations Analyst for safety app Citizen. He was previously a staff writer at BioCentury, and has worked for SpringerNature journals including Nature Biotechnology and Nature Neuroscience. Mark lives in New Jersey with his wife and three children. Follow Mark on Twitter @MarkZipkin.

Articles by Mark Zipkin

News and Trends 7 Oct 2021

Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery

Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts to use artificial intelligence to fuel drug discovery, with global tech investors often taking the…

October 7, 2021 - 5 minutesmins - By Mark Zipkin

Expert Advice 5 Oct 2021

How to Choose the Right Headquarters for Your Biotech Startup

Choosing where to plant your biotech company’s roots is a fundamental question driven by access to capital, talent, and infrastructure. But the pandemic is accelerating a decentralization movement, changing the…

October 5, 2021 - 6 minutesmins - By Mark Zipkin

Expert Advice 18 Aug 2021

How to Pitch Your Biotech Startup to a Life Sciences Investor

You’ve got the idea. You’ve got the science. You’ve got the team. Now all you need is the money, but that can be a tricky step for a new biotech…

August 18, 2021 - 9 minutesmins - By Mark Zipkin

News and Trends 17 Aug 2021

Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology

Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies beyond Covid-19. Based in Boston, US, Translate Bio develops mRNA…

August 17, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 28 Jul 2021

Microbiome Medicines Could Power Up CAR-T Cell Therapies

The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A…

July 28, 2021 - 5 minutesmins - By Mark Zipkin

IP intellectual property biotech startup

Expert Advice 19 Jul 2021

How to Protect Your Intellectual Property as a Biotech Startup

Biotechs always start with great scientific ideas, but if you can’t protect them, you can’t see them through to execution. Companies need to start developing long-term intellectual property strategies almost…

July 19, 2021 - 9 minutesmins - By Mark Zipkin

Expert Advice 16 Jun 2021

What Makes a Biotech Executive Stand Out?

Talented executives are always in demand in the biotech industry. Leaders who stand out in the field demonstrate flexibility to deal with change and failure, as well as a track…

June 16, 2021 - 6 minutesmins - By Mark Zipkin

News and Trends 28 May 2021

Startup Creator Launched to Fill Europe’s Microbiome Translational Gap

With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the goal of priming the translational pump in hot areas where European academics have already made…

May 28, 2021 - 6 minutesmins - By Mark Zipkin

Expert Advice 17 May 2021

How to Spend Your Biotech Startup’s Money

Biotech investment rounds tend to draw big headlines, but experienced players know the real work is done in between them. Avoiding some common pitfalls can make the difference between petering…

May 17, 2021 - 6 minutesmins - By Mark Zipkin

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint…

April 29, 2021 - 5 minutesmins - By Mark Zipkin

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of…

April 15, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 1 Apr 2021

Have European Investors Missed the Exosome ‘Gold Rush’?

When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome therapies seriously. But a lack of European investors in the…

April 1, 2021 - 5 minutesmins - By Mark Zipkin

Newsletter Signup

"*" indicates required fields

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering